Literature DB >> 1728669

Causes of primary graft failure after in situ saphenous vein bypass grafting.

M C Donaldson1, J A Mannick, A D Whittemore.   

Abstract

In situ saphenous vein bypass grafts originating in the groin were performed in 455 consecutive patients. Primary failure occurred in 92 grafts during follow-up, including 22 (4.8%) with nonocclusive stenosis and 70 (15.4%) with occlusion. The cause for failure could not be determined in seven grafts; 104 contributory causes were identified in the remaining 85 grafts. Among the 104 likely causes, 66 (63%) were intrinsic to the graft itself and contributed to failure of 55 (12.1%) of 455 grafts. These causes included perianastomotic stenosis (48), vein stricture (14), focal vein stenosis (10), valvulotome injury (9), kink (6), retained valve leaflet (4), intimal flap (3), and residual arteriovenous fistula (2). Among these intrinsic causes, 20 were directly related to the in situ technique, contributing to failure of 15 (3.3%) of 455 grafts. Thirty-eight (37%) of the 104 causes were extrinsic to the graft, including compromised inflow (2) or outflow (19), hypercoagulability (9), systemic hypotension (6), and graft sepsis (2). Hypothetically, improvements in technique, patient selection, and perioperative management might have eliminated 46 (44%) of 104 causes of primary graft failure. Delayed graft and anastomotic stenosis and late progression of outflow disease remain resistant to modern therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1728669     DOI: 10.1067/mva.1992.32984

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

1.  Audit of attendance rates for an infra-inguinal graft surveillance programme--how complete is your graft surveillance?

Authors:  J McIntosh; T J Crook; K R Poskitt; M R Whyman
Journal:  Ann R Coll Surg Engl       Date:  2002-05       Impact factor: 1.891

2.  Aspirin monotherapy vs. dual antiplatelet therapy in diabetic patients following coronary artery bypass graft (CABG): where do we stand?

Authors:  Salem Salem; Sameh Askandar; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2017-05

Review 3.  Peripheral artery disease. Part 2: medical and endovascular treatment.

Authors:  Mitchell D Weinberg; Joe F Lau; Kenneth Rosenfield; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-06-14       Impact factor: 32.419

4.  Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long-term graft patency and limb salvage.

Authors:  T M Bergamini; S M George; H T Massey; P K Henke; T W Klamer; G E Lambert; F B Miller; R N Garrison; J D Richardson
Journal:  Ann Surg       Date:  1995-05       Impact factor: 12.969

5.  Is thickening of the basal lamina in the saphenous vein a hallmark of smoking?

Authors:  D J Higman; J T Powell; R M Greenhalgh; A Coady; J Moss
Journal:  Br Heart J       Date:  1994-01

6.  Repair and follow-up of leg arteries with vein grafts.

Authors:  G L Moneta; J M Porter
Journal:  West J Med       Date:  1993-12

7.  Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass.

Authors:  Brian W Nolan; Randall R De Martino; David H Stone; Andres Schanzer; Philip P Goodney; Daniel W Walsh; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2011-07-29       Impact factor: 4.268

Review 8.  Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway.

Authors:  Masayuki Sugimoto; Dai Yamanouchi; Kimihiro Komori
Journal:  Surg Today       Date:  2009-05-27       Impact factor: 2.549

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.